NasdaqGM - Delayed Quote • USD
Arcturus Therapeutics Holdings Inc. (ARCT)
At close: May 28 at 4:00 PM EDT
After hours: May 28 at 7:46 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | -1.58 | -0.7 | -2.96 | -1.02 |
| Low Estimate | -2.11 | -1.85 | -5.28 | -6.93 |
| High Estimate | -0.89 | 0.67 | -0.39 | 3.65 |
| Year Ago EPS | -1.98 | -0.61 | -1 | -2.96 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 7 |
| Avg. Estimate | 21.7M | 46.7M | 181.84M | 254.98M |
| Low Estimate | 10M | 10M | 138.51M | 94.96M |
| High Estimate | 30M | 80M | 228M | 509.95M |
| Year Ago Sales | 10.52M | 45.14M | 169.93M | 181.84M |
| Sales Growth (year/est) | 106.30% | 3.50% | 7.00% | 40.20% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.21 | -1.69 | -0.99 | -1.19 |
| EPS Actual | -1.98 | -0.61 | -0.32 | -1 |
| Difference | -1.77 | 1.08 | 0.67 | 0.19 |
| Surprise % | -842.90% | 63.90% | 67.70% | 16.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.58 | -0.7 | -2.96 | -1.02 |
| 7 Days Ago | -1.58 | -0.7 | -2.96 | -1.02 |
| 30 Days Ago | -1 | -0.16 | -2.51 | 0.22 |
| 60 Days Ago | -0.89 | -0.21 | -2.35 | 0.6 |
| 90 Days Ago | -1.02 | -0.45 | -3.29 | 2.87 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 2 | 2 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ARCT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 20.20% | -- | -- | 7.90% |
| Next Qtr. | -14.80% | -- | -- | 10.20% |
| Current Year | -196.00% | -- | -- | 4.80% |
| Next Year | 65.50% | -- | -- | 12.50% |
| Next 5 Years (per annum) | -- | -- | -- | 11.27% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Canaccord Genuity: Buy to Buy | 5/10/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/20/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 3/11/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/8/2024 |
| Maintains | Wells Fargo: Overweight to Overweight | 3/8/2024 |
| Maintains | Citigroup: Buy to Buy | 2/8/2024 |
Related Tickers
ACHL Achilles Therapeutics plc
0.9200
+1.10%
STOK Stoke Therapeutics, Inc.
14.07
-2.39%
VIR Vir Biotechnology, Inc.
10.73
+1.71%
CABA Cabaletta Bio, Inc.
10.67
-2.29%
HRMY Harmony Biosciences Holdings, Inc.
29.42
-1.77%
RNA Avidity Biosciences, Inc.
26.32
-4.12%
EDIT Editas Medicine, Inc.
5.32
-5.51%
ABUS Arbutus Biopharma Corporation
3.3500
+1.82%
NKTX Nkarta, Inc.
6.47
+0.47%
BCYC Bicycle Therapeutics plc
22.98
-0.22%